MyChesCo on MSN
Palvella Therapeutics Receives Second Year of FDA Grant Funding for Phase 3 SELVA Trial
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has received the second year of funding under its U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback